Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: SLC35B2

Gene summary for SLC35B2

Gene summary.

Gene information	Species	Human
	Gene symbol	SLC35B2
	Gene ID	347734
	Gene name	solute carrier family 35 member B2
	Gene Alias	PAPST1
	Cytomap	6p21.1
	Gene Type	protein-coding
	GO ID	GO:0006082
	UniProtAcc	Q8TB61

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
347734	SLC35B2	HTA11_3410_2000001011	Human	Colorectum	AD	1.02e-03	1.66e-01	0.0155
347734	SLC35B2	HTA11_2487_2000001011	Human	Colorectum	SER	6.65e-03	2.19e-01	-0.1808
347734	SLC35B2	HTA11_1938_2000001011	Human	Colorectum	AD	1.75e-09	3.58e-01	-0.0811
347734	SLC35B2	HTA11_78_2000001011	Human	Colorectum	AD	7.86e-06	2.99e-01	-0.1088
347734	SLC35B2	HTA11_347_2000001011	Human	Colorectum	AD	3.90e-04	1.92e-01	-0.1954
347734	SLC35B2	HTA11_696_2000001011	Human	Colorectum	AD	2.06e-09	2.41e-01	-0.1464
347734	SLC35B2	HTA11_1391_2000001011	Human	Colorectum	AD	7.81e-05	2.55e-01	-0.059
347734	SLC35B2	HTA11_866_3004761011	Human	Colorectum	AD	1.22e-06	2.64e-01	0.096
347734	SLC35B2	HTA11_4255_2000001011	Human	Colorectum	SER	9.21e-03	4.02e-01	0.0446
347734	SLC35B2	HTA11_10711_2000001011	Human	Colorectum	AD	7.24e-04	2.26e-01	0.0338
347734	SLC35B2	HTA11_7696_3000711011	Human	Colorectum	AD	2.62e-08	2.55e-01	0.0674
347734	SLC35B2	HTA11_99999970781_79442	Human	Colorectum	MSS	7.95e-14	2.80e-01	0.294
347734	SLC35B2	HTA11_99999965062_69753	Human	Colorectum	MSI-H	4.18e-05	5.23e-01	0.3487
347734	SLC35B2	HTA11_99999965104_69814	Human	Colorectum	MSS	1.37e-11	4.52e-01	0.281
347734	SLC35B2	HTA11_99999971662_82457	Human	Colorectum	MSS	2.98e-11	2.98e-01	0.3859
347734	SLC35B2	HTA11_99999973899_84307	Human	Colorectum	MSS	1.55e-05	3.09e-01	0.2585
347734	SLC35B2	HTA11_99999974143_84620	Human	Colorectum	MSS	2.62e-11	2.54e-01	0.3005
347734	SLC35B2	LZE2T	Human	Esophagus	ESCC	4.54e-02	6.62e-01	0.082
347734	SLC35B2	LZE4T	Human	Esophagus	ESCC	2.98e-04	1.46e-01	0.0811
347734	SLC35B2	LZE7T	Human	Esophagus	ESCC	4.85e-05	4.91e-01	0.0667

Page: 1 2 3 4 5 6 7

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0033875	Colorectum	AD	ribonucleoside bisphosphate metabolic process	42/3918	128/18723	1.12e-03	1.02e-02	42
GO:0034032	Colorectum	AD	purine nucleoside bisphosphate metabolic process	42/3918	128/18723	1.12e-03	1.02e-02	42
GO:0034035	Colorectum	AD	purine ribonucleoside bisphosphate metabolic process	11/3918	21/18723	1.43e-03	1.22e-02	11
GO:0050427	Colorectum	AD	3'-phosphoadenosine 5'-phosphosulfate metabolic process	11/3918	21/18723	1.43e-03	1.22e-02	11
GO:0015748	Colorectum	AD	organophosphate ester transport	42/3918	140/18723	7.04e-03	4.31e-02	42
GO:00061631	Colorectum	SER	purine nucleotide metabolic process	109/2897	396/18723	4.26e-10	5.44e-08	109
GO:00091501	Colorectum	SER	purine ribonucleotide metabolic process	103/2897	368/18723	4.69e-10	5.68e-08	103
GO:00725211	Colorectum	SER	purine-containing compound metabolic process	113/2897	416/18723	4.80e-10	5.68e-08	113
GO:00092591	Colorectum	SER	ribonucleotide metabolic process	104/2897	385/18723	3.27e-09	3.04e-07	104
GO:00196931	Colorectum	SER	ribose phosphate metabolic process	105/2897	396/18723	8.15e-09	7.14e-07	105
GO:00091171	Colorectum	SER	nucleotide metabolic process	122/2897	489/18723	2.50e-08	1.76e-06	122
GO:00067531	Colorectum	SER	nucleoside phosphate metabolic process	122/2897	497/18723	6.64e-08	4.33e-06	122
GO:00091521	Colorectum	SER	purine ribonucleotide biosynthetic process	48/2897	169/18723	1.27e-05	4.01e-04	48
GO:00092601	Colorectum	SER	ribonucleotide biosynthetic process	49/2897	182/18723	4.85e-05	1.19e-03	49
GO:00463901	Colorectum	SER	ribose phosphate biosynthetic process	50/2897	190/18723	7.70e-05	1.72e-03	50
GO:00725221	Colorectum	SER	purine-containing compound biosynthetic process	51/2897	200/18723	1.55e-04	3.01e-03	51
GO:00061641	Colorectum	SER	purine nucleotide biosynthetic process	49/2897	191/18723	1.77e-04	3.30e-03	49
GO:00159311	Colorectum	SER	nucleobase-containing compound transport	54/2897	222/18723	3.65e-04	5.67e-03	54
GO:00091651	Colorectum	SER	nucleotide biosynthetic process	58/2897	254/18723	1.21e-03	1.38e-02	58
GO:19012931	Colorectum	SER	nucleoside phosphate biosynthetic process	58/2897	256/18723	1.47e-03	1.59e-02	58

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

SLC35B2

SNV

Missense_Mutation

rs762279662

c.1232C>T

p.Ala411Val

p.A411V

Q8TB61

protein_coding

tolerated(0.11)

probably_damaging(0.999)

TCGA-A8-A08L-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Unknown

SLC35B2

SNV

Missense_Mutation

c.707N>C

p.Glu236Ala

p.E236A

Q8TB61

protein_coding

deleterious(0.01)

possibly_damaging(0.837)

TCGA-BH-A0E7-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

SLC35B2

SNV

Missense_Mutation

rs752687684

c.241N>A

p.Val81Met

p.V81M

Q8TB61

protein_coding

deleterious(0.01)

possibly_damaging(0.887)

TCGA-C8-A275-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

SLC35B2

SNV

Missense_Mutation

c.263C>A

p.Ala88Asp

p.A88D

Q8TB61

protein_coding

tolerated(0.47)

benign(0.005)

TCGA-D8-A140-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin+cyclophosphamid

SLC35B2

SNV

Missense_Mutation

c.474G>A

p.Met158Ile

p.M158I

Q8TB61

protein_coding

tolerated(0.3)

benign(0.115)

TCGA-E2-A159-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cyclophosphamide

SLC35B2

SNV

Missense_Mutation

rs772679565

c.290G>A

p.Arg97Gln

p.R97Q

Q8TB61

protein_coding

tolerated(0.27)

benign(0.034)

TCGA-PE-A5DE-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

taxotere

SLC35B2

insertion

Frame_Shift_Ins

novel

c.754_755insGATA

p.Met252ArgfsTer32

p.M252Rfs*32

Q8TB61

protein_coding

TCGA-AO-A0J5-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Other, specify in notesBisphosphonate

zoledronic

SLC35B2

insertion

In_Frame_Ins

novel

c.752_753insGATGCCCTGTTTGCCTATAAGATGTCATCGGTG

p.Ser251delinsArgMetProCysLeuProIleArgCysHisArgCys

p.S251delinsRMPCLPIRCHRC

Q8TB61

protein_coding

TCGA-AO-A0J5-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Other, specify in notesBisphosphonate

zoledronic

SLC35B2

deletion

Frame_Shift_Del

novel

c.999delN

p.His334ThrfsTer38

p.H334Tfs*38

Q8TB61

protein_coding

TCGA-EW-A2FV-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

docetaxel

SLC35B2

SNV

Missense_Mutation

rs138499828

c.1252N>T

p.Arg418Trp

p.R418W

Q8TB61

protein_coding

deleterious(0.03)

possibly_damaging(0.803)

TCGA-C5-A1BQ-01

Cervix

cervical & endocervical cancer

Female

>=65

III/IV

Chemotherapy

cisplatin

Page: 1 2 3 4

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1